Table 3.
Percent of patients who reported an adverse event by daily dose and treatment period
| Treatment period | Daily dosage of OROS methylphenidate (N =370)
|
||||
|---|---|---|---|---|---|
| 18 mg | 36 mg | 54 mg | 72 mg | 90 mg | |
| Week 1 | 46% (46/101) | 44% (104/237) | 36% (4/11) | 0% (0/1) | 100% (1/1) |
| Week 3 | 38% (9/24) | 30% (40/133) | 49% (76/154) | 49% (16/33) | 0% (0/4) |
| Week 7 | 33% (7/21) | 23% (19/82) | 26% (29/110) | 31% (20/65) | 38% (12/32) |
Notes: Numerator is number of patients reporting any adverse event; denominator is total number of patients in the same dosage and treatment week. Excludes patients who took no drug on the visit day for the treatment week or did not attend the visit day (see Figure 1).
Abbreviation: OROS, osmotic release oral system.